用于在虚拟改良的 Box and Block 测试期间定量评估运动和肌肉活动的设置
January 12th, 2024
1.4K views
此处描述的协议旨在加强上肢缺陷的定量评估，目的是开发额外的技术，以便在临床和家中进行远程评估。虚拟现实和生物传感器技术与标准临床技术相结合，提供对神经肌肉系统功能的见解。
在西弗吉尼亚大学的神经工程与康复实验室，我们研究感觉运动控制的功能机制，并开发客观的评估工具来评估运动技能和运动障碍。远程或虚拟护理已成为解决医疗保健差异的一种有前途的手段。然而，迫切需要定量描述用于这些应用的运动技能。
我们的协议旨在使临床医生和研究人员能够获得有关复杂运动的高分辨率数据，以便更好地远程评估运动缺陷。该协议旨在通过自动化家庭运动评估来简化复杂和未充分利用的康复技术。它的主要优势在于集成虚拟现实、动作捕捉和肌电图。
例如，具有手部追踪功能的 VR 头戴式设备可以捕捉运动以进行首次分析，而 EMG 手环则用于估计虚拟测试期间的肌肉性能。
概述
该协议旨在通过将虚拟现实和生物传感器技术与标准临床技术相结合，增强上肢缺陷的定量评估。目标是促进临床环境和家庭中远程评估运动技能。
关键研究组成部分
科学领域
- 神经工程学
- 康复
- 运动控制评估
背景
- 远程护理解决医疗保健差距。
- 运动技能的定量表征至关重要。
- 高分辨率的复杂运动数据对于更好的评估是必要的。
- 当前的康复技术未得到充分利用。
研究目的
- 使临床医生能够远程评估运动缺陷。
- 简化家庭使用的康复技术。
- 自动化运动评估过程。
使用的方法
- 虚拟现实技术的整合。
- 运动捕捉技术。
- 肌电图用于肌肉活动评估。
- 标准临床技术用于全面评估。
主要结果
- 增强定量评估上肢缺陷的能力。
- 改善对神经肌肉系统功能的洞察。
- 促进远程评估能力。
- 简化复杂的康复技术。
结论
- 该协议为远程评估提供了一个稳健的框架。
- 技术组合可以带来更好的患者结果。
- 未来的应用可能进一步弥合医疗保健差距。
常见问题
该协议的主要目标是什么？
主要目标是增强上肢缺陷的定量评估以实现远程评估。
该协议如何整合技术？
它结合了虚拟现实、运动捕捉和肌电图与标准临床技术。
为什么远程评估很重要？
远程评估有助于解决医疗保健差距并为更多患者提供护理。
该协议的主要优势是什么？
主要优势包括高分辨率数据收集和简化的康复技术。
谁可以从该协议中受益？
临床医生和研究人员可以受益，通过获得更好的运动缺陷评估。
该研究使用了哪些技术？
研究使用了虚拟现实、运动捕捉和肌电图技术。
Executive Industry Relevance
Quantitative assessment of motion and muscle activity using integrated virtual reality and biosensor platforms addresses a critical gap in remote evaluation of motor function. This capability enables high-resolution, objective measurement of movement impairment, supporting early discovery and translational research in neuromuscular and rehabilitation-focused biopharma pipelines. The approach enhances predictive confidence for target validation and informs risk-adjusted advancement decisions in therapeutic development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables objective interrogation of neuromuscular function and pathway involvement in disease models.
- Supports biological de-risking by providing quantitative, reproducible movement and muscle activation data.
- Facilitates functional target validation through high-resolution assessment of motor deficits.
Screening & Assay Development
- Prepares validated, quantitative movement assays for downstream compound screening workflows.
- Standardizes assessment protocols to ensure reproducibility and comparability across studies.
- Generates scalable, platform-ready data for reliable evaluation of therapeutic interventions.
Translational & Preclinical Research
- Aligns quantitative movement and EMG outputs with disease-relevant functional endpoints.
- Enables continuity from early discovery through preclinical validation of neuromuscular therapies.
- Supports risk-adjusted decisions by providing mechanistic insight into therapeutic impact on motor function.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by enabling objective, quantitative assessment of motor function and muscle activity in both controlled and remote settings.
- Discovery Biology: Provides high-resolution data for hypothesis testing and mechanistic de-risking in neuromuscular research.
- Screening: Delivers standardized, reproducible movement and EMG assays for compound evaluation.
- Analytics: Supplies quantitative outputs for statistical comparison of intervention effects on motor performance.
- Translational Research: Bridges discovery and preclinical validation by aligning functional readouts with clinical endpoints.
- Enterprise Reuse: Establishes a reusable platform for remote, quantitative assessment across multiple therapeutic programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuromuscular target validation.
- Operational Value: Standardizes and automates movement assessment for scalable, reproducible data generation.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by providing robust functional endpoints.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuromuscular and rehabilitation-focused assets.
Implementation Considerations
- Requires expertise in motion capture, EMG, and virtual reality system integration.
- Demands dedicated instrumentation and synchronized analytical infrastructure for data acquisition.
- Necessitates cross-team standardization of protocols and data formats for reproducibility.
- May require adaptation for different model systems or patient populations.
- Dependent on reliable remote connectivity and user compliance for at-home assessments.
Biopharma FAQs
Why does null hypothesis testing matter for virtual Box and Block data?
Null hypothesis testing enables objective evaluation of whether observed differences in motion or muscle activity during the virtual Box and Block test are statistically significant, supporting robust target validation and mechanistic de-risking in neuromuscular research.
How does independent variable isolation fit the VR-EMG workflow?
Isolating independent variables, such as task parameters or intervention conditions, within the VR-EMG workflow allows researchers to attribute changes in motor performance or muscle activation to specific experimental manipulations, enhancing discovery-stage confidence.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative measurements of movement and EMG outputs enable precise comparison of functional outcomes across conditions, facilitating data-driven decisions in screening and translational research pipelines.
Why are replication requirements critical for cross-functional collaboration?
Replication ensures that movement and muscle activity data are reproducible across teams and studies, supporting cross-functional collaboration and standardization in multi-site or multi-program biopharma environments.
What statistical analysis capabilities are required before implementation?
Robust statistical analysis capabilities are needed to process and interpret high-resolution motion and EMG data, ensuring that outputs meet the rigor required for portfolio advancement and regulatory documentation.
